Rituximab is a therapy no used in both indolent and aggressive B cell lymphomas. What is the mechanism of action of Rituximab? List the major disorders for which Rituximab is approved for use.
Recall that CD20 is expressed on over 90% of B cells and is a protein that is not shed or internalized.
Rituximab is an anti-CD20 chimeric monoclonal antibody that on contact to CD20 on the surface of a B cell causes cytotoxicity mediated by compliment and antibody-dependent cellular cytotoxicity.
Indications for Rituximab use:
- Treatment of CD20 positive lymphoproliferative disorders
- Treatment of Connective tissue disease such as Rheumatoid arthritis
- Can be requested on special access for second line therapies in autoimmune disorders such as immune thrombocytopenia, autoimmune hemolytic anemia, or Thrombotic Thrombocytopenia Purpura